Phase I Dose-Escalation Study of TORL-2-307-MAB in Patients With Advanced Cancer
Summary
The purpose of this phase I study is to evaluate the safety and feasibility of TORL-2-307-MAB in patients with advanced solid tumors, including pancreatic cancer.
General Information
NCT#: NCT05159440
Study ID: TORL2307MAB-001
Trial Phase: Phase I
Trial Sponsor: TORL Biotherapeutics, LLC
Therapies Used in This Trial: TORL-2-307-MAB